National Healthcare Agreement: PI 15–Effective management of diabetes, 2021
Identifying and definitional attributes
|Metadata item type:||Indicator|
|Indicator type:||Progress measure|
|Short name:||PI 15–Effective management of diabetes, 2021|
|Registration status:||Health, Standard 03/07/2020|
Proportion of people with known diabetes who have an HbA1c (glycated haemoglobin) level less than or equal to 7.0%
|Indicator set:||National Healthcare Agreement (2021) Health, Standardisation pending 03/08/2020|
|Outcome area:||Primary and Community Health Health, Standard 07/07/2010|
Collection and usage attributes
The National Health Measures Survey component of the 2011–12 Australian Health Survey (ABS cat. no. 4364.0.55.005) included a fasting plasma glucose test and an HbA1c test. For this indicator, the fasting plasma glucose test is used in the determination of people with known diabetes and the HbA1c test is used in the determination of effective management of diabetes. Persons with known diabetes who have an HbA1c result of less than or equal to 7.0% are considered to be managing their diabetes effectively.
Known diabetes is defined as persons self-reporting that they had ever been told by a doctor or nurse that they have diabetes and:
Excludes persons who did not fast for 8 hours or more prior to their blood test.
Reported for persons aged between 18 and 69.
Excludes women with gestational diabetes.
Analysis by remoteness and Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socio-Economic Disadvantage (IRSD) is based on usual residence of the person (subject to data availability).
Presented as a percentage.
95% confidence intervals and relative standard errors calculated for rates.
100 x (Numerator ÷ Denominator)
Number of persons aged between 18 and 69 with known diabetes, as determined by a fasting plasma glucose test, who have an HbA1c level of less than or equal to 7.0%.
|Numerator data elements:|
Number of persons aged between 18 and 69 with known diabetes, as determined by a fasting plasma glucose test.
|Denominator data elements:|
State and territory, by:
Nationally, by (all not reported this cycle):
Some disaggregation may result in numbers too small for publication.
|Disaggregation data elements:|
Most recent data available for 2021 National Healthcare Agreement performance reporting: 2011–12 (total population, non-Indigenous: AHS); 2012–13 (Indigenous only: AATSIHS).
NO NEW DATA FOR 2021 REPORTING.
|Unit of measure:||Person|
Indicator conceptual framework
|Framework and dimensions:||Effectiveness|
Data source attributes
National Healthcare Agreement
|Organisation responsible for providing data:|
Australian Bureau of Statistics
|Further data development / collection required:|
Specification: Final, the measure meets the intention of the indicator.
Source and reference attributes
Australian Bureau of Statistics (ABS) 2013. Australian Health Survey: Biomedical Results for Chronic Diseases, 2011–12, ABS cat. no. 4364.0.55.005. Canberra: ABS. Viewed 11 May 2020, https://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/4364.0.55.005
|Related metadata references:|
See also National Healthcare Agreement: PB c–Better health: reduce the age-adjusted prevalence rate for Type 2 diabetes to 2000 levels (equivalent to a national prevalence rate (for 25 years and over) of 7.1 per cent) by 2023, 2021 Health, Standard 03/07/2020
See also National Healthcare Agreement: PI 10–Prevalence of Type 2 diabetes, 2021 Health, Standard 03/07/2020
Supersedes National Healthcare Agreement: PI 15–Effective management of diabetes, 2020 Health, Standard 13/03/2020